Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bivalirudin vs Heparin in STEMI patients undergoing PCI (BRIGHT-4)
NCT03822975Completed
- Sponsor
- General Hospital of the Northern Theater Command
- Start
- Feb 2019
- Primary completion
- May 2022
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of bivalirudin in ST elevation myocardial infarction (STEMI), sponsored by General Hospital of the Northern Theater Command. Primary endpoint: Composite of all-cause death or BARC type 3-5 bleeding at 30 days. Started Feb 2019; status: completed.
02
Drugs
bivalirudin
03
Conditions
ST elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT03822975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03822975.